Elekta

Regulatory Filings • Nov 2, 2009

ELEKTA CONTINUES TO GROW IN KEY EMERGING MARKETS DELIVERS CLINICAL SOLUTIONS TO NINE CANCER CLINICS IN RUSSIA

Press Release

Stockholm, Sweden, November 2, 2009

Elekta is improving the availability of cancer care for Russian patients by delivering clinical solutions, services and training to a number of key hospitals and cancer centers throughout Russia.

Elekta has won seven out of ten tenders being part of the new Russian National Oncology Program. The program was initiated under the auspices of Prime Minister Vladimir Putin in early 2009 with the aim to improve prevention and early detection of cancer.

Currently, patients in Russia are diagnosed with cancer mostly at stages III and IV, negatively affecting the survival rate and with expensive medical and drug treatment required. The program is considered an important step by the Russian Government to increase the life span for the Russian people.

"By 2012, the situation must be changed so that identification and treatment of cancer patients will already happen at stages I and II of the disease", said the Russian Minister of Health, Tatiana Golikova at the presentation of the program.

As part of the program, Elekta will deliver four Elekta Synergy®, two Precise Treatment System™ and one Elekta Axesse™ to hospitals and cancer centers throughout the country. Engineers and medical physicists from Elekta and its Russian distributor MSM-Medimpex will provide training for all medical staff as well as services.

In addition, two other key centers in Russia recently purchased two Elekta Axesse™ for their stereotactic program.

"We are proud to be a part of the expansion of cancer care in Russia, and in making the latest clinical treatment solutions available to more patients throughout the country", says Olof Sandén, Executive Vice President for Elekta Europe, Africa, Latin America and Middle East.

Elekta is continuing to execute on its plan for geographical expansion in key emerging markets, where Russia is one of several geographical areas with a large unmet need for cancer care.

"We have created a new structure and strategies supporting our focus on emerging markets where a large number of patients can benefit from life-saving technologies at an affordable cost per patient", says Mr. Sandén.

******

For further information, please contact:

Stina Thorman, Investor Relations, Elekta AB Tel: +46 8 587 254 37, +46 70 778 60 10, e-mail: stina.thorman@elekta.com

Michelle Lee, Director, Marketing Services, Elekta Inc. Tel: +1 770-670-2447, e-mail: michelle.lee@elekta.com

About Elekta

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated state of the art tools and treatment planning systems for radiation therapy and radiosurgery, as well as workflow enhancing software systems across the spectrum of cancer care.

Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives, making the future possible today.

Today, Elekta solutions in oncology and neurosurgery are used in over 5,000 hospitals globally, and every day more than 100,000 patients receive diagnosis, treatment or follow-up with the help of a solution from the Elekta Group.

Elekta employs around 2,500 employees globally. The corporate headquarter is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. For more information about Elekta, please visit www.elekta.com.